LabGenomics is experiencing a surge in stock prices following news of strengthening its sales system for expanding its diagnostic testing business in the United States.
According to the Korea Exchange, as of 2:27 PM, LabGenomics shares rose by 173 won (29.93%) to 751 won compared to the previous trading day.
The company announced that it held a National Sales Meeting in New Jersey last month, attended by sales personnel from across the U.S., which is believed to have boosted investor sentiment.
This event marked the first company-wide sales meeting since the recent integration of two U.S. clinical laboratory certification (CLIA) facilities under the single brand 'LabGenomics.' Sales representatives from 27 states gathered to share sales cases and expertise in key testing areas, including cancer diagnostics, digital pathology-based tests, skin pathology tests, and blood-based Alzheimer’s diagnostics with 'Lumipulse.'
LabGenomics plans to expand its sales scope for general diagnostic and cancer diagnostic tests nationwide, targeting large hospitals and clinics for cross-selling and expanding test menus.
A LabGenomics official stated, "In the second half of the year, we expect to see significant revenue growth and improved profitability in our U.S. operations, driven by Team Murray's sales strategy and the performance of the sales personnel who joined earlier this year."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.